Quality and safety requirements for sustainable phage therapy products by Pirnay, Jean-Paul et al.
PERSPECTIVE
Quality and Safety Requirements for Sustainable Phage Therapy
Products
Jean-Paul Pirnay & Bob G. Blasdel & Laurent Bretaudeau & Angus Buckling & Nina Chanishvili & Jason R. Clark & Sofia Corte-Real &
Laurent Debarbieux & Alain Dublanchet & Daniel De Vos & Jérôme Gabard & Miguel Garcia & Marina Goderdzishvili & Andrzej Górski &
John Hardcastle & Isabelle Huys & Elizabeth Kutter & Rob Lavigne & Maia Merabishvili & Ewa Olchawa & Kaarle J. Parikka & Olivier Patey &
Flavie Pouilot & Gregory Resch & Christine Rohde & Jacques Scheres & Mikael Skurnik & Mario Vaneechoutte & Luc Van Parys &
Gilbert Verbeken & Martin Zizi & Guy Van den Eede
Received: 2 December 2014 /Accepted: 30 December 2014
# The Author(s) 2015. This article is published with open access at SpringerLink.com
ABSTRACT The worldwide antibiotic crisis has led to a renewed
interest in phage therapy. Since time immemorial phages control
bacterial populations on Earth. Potent lytic phages against bacterial
pathogens can be isolated from the environment or selected from a
collection in a matter of days. In addition, phages have the capacity to
rapidly overcome bacterial resistances, which will inevitably emerge.
To maximally exploit these advantage phages have over conventional
drugs such as antibiotics, it is important that sustainable phage prod-
ucts are not submitted to the conventional long medicinal product
development and licensing pathway. There is a need for an adapted
framework, including realistic production and quality and safety re-
quirements, that allowsa timely supplying of phage therapy products
for ‘personalized therapy’ or for public health or medical emergen-
cies. This paper enumerates all phage therapy product related quality
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and safety risks known to the authors, as well as the tests that can be
performed to minimize these risks, only to the extent needed to
protect the patients and to allow and advance responsible phage
therapy and research.
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Antimicrobial resistance in bacteria is an increasingly serious
threat in every part of the world [1].Without action, the world
could be heading towards a post-antibiotic era in which com-
mon infections become fatal and currently routine surgeries
become impossible. New initiatives to tackle the problem of
antibiotic resistance are urgently needed.
One promising solution is the therapeutic use of bacterio-
phages – the viruses of bacteria, also known as phages – to
treat bacterial infections. When discovered in the early twen-
tieth century, phages were immediately applied in medicine
(phage therapy) with variable success. After World War II,
Western industry and policymakers preferred antibiotics,
which at the time had obvious advantages in terms of breadth
of coverage and ease of production and patentability, and
phage therapy was pushed into the background. Today,
phage therapy is again put forward as a potential way to
address the current antibiotic crisis [2, 3].
Since time immemorial, phages have controlled bacterial
populations on our planet, locked in an evolutionary arms race
with their hosts (consisting of the repeated emergence of new
phage infectivity and bacterial defense mutations). The capacity
of bacteriophages to rapidly overcome bacterial resistancemakes
them suitable for flexible therapeutic applications. Tomaximally
exploit this key advantage of phages over conventional ‘static’
drugs such as traditional small molecule-type antibiotics, it is
important that sustainable phage products are not submitted to
the conventional long medicinal product development and li-
censing pathway [4]. A key goal for the modern phage therapy
community must be the development and validation of an
expedited product development and licensing pathway in con-
sultation with policymakers and competent authorities.
Georgian and Polish phage therapy centers maintain ex-
tensive therapeutic phage collections, which are regularly
enriched with new phages, thus widening the total host range
of the collection and adapting the collection to changing
bacterial populations (with regard to host range and antibiotic
resistance as well as phage resistance). Moreover, the effec-
tiveness of phages can be readily improved by in vitro selection
of (natural) phage mutants that exhibit an increased infectivity
range. For example, it is possible to obtain potent lytic phages
against problematic enteroaggregative Escherichia coli strains by
isolation of new phages from the environment or by selection
and adaptation of phages from an existing collection, and this
often in a matter of days [5]. As such, phages could probably
have been used to help control the O104:H4 (hybrid EAggEC
STEC/VTEC pathotype) E. coli outbreak that caused the
death of more than 50 patients in Germany in 2011. Unfor-
tunately, authorized use of phages would not have been
possible in this otherwise feasible context because under the
existing medicinal product legislation such an anti-O104:H4
phage preparation would have taken years to develop, pro-
duce and register. Since phages are species and often even
strain-specific, it is very likely that current O104:H4 specific
phage preparations will not be effective against future epi-
demic enteroaggregative E. coli strains. ‘Broad spectrum’
phage cocktails active against bacteria that are likely to cause
problems in the future could be developed in advance and
used as a first line treatment for acute healthcare problems
(e.g., foodborne disease outbreaks and bacterial bioweapon
threats). However, we need to keep in mind that some of these
cocktails will not always work due to the greater biodiversity
outside of the laboratory and the existing resistance to specific
phages. The cocktails that initially work will need to be regu-
larly updated (e.g., supplemented with new phages in response
to the evolution of phage resistance and the involvement of
new circulating bacterial strains). There are indications that
bacterial resistance to phages, even to cocktails containing
multiple potent phages, will inevitably occur [6].
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Table I Expert Consensus Quality and Safety Requirements for Sustainable Phage Therapy Products
A. Production environment
When production activities include the processing of intermediate, bulk or finished phage products exposed to the environment, this must take place in an
environment with specified air quality and cleanliness in order to minimize the risk of contamination. The effectiveness of these measures must be validated and
monitored. Where intermediate, bulk or finished products are exposed to the environment during processing, without a subsequent microbial inactivation
process, an air quality with particle counts and microbial colony counts equivalent to those of Grade A as defined in the current European Guide to Good
Manufacturing Practice (GMP), Annex 1 and Directive 2003/94/EC is required with a background environment at least equivalent to GMP Grade D in terms of
particles and microbial counts. The biosafety level (BSL) is determined by the host bacteria used in the production processes (e.g., BSL-2 for Pseudomonas
aeruginosa).
B. Production processes, equipment and materials
All equipment and material must be designed and maintained to suit its intended purpose and must minimize any hazard to recipients and staff. All critical
equipment and technical devices must be identified and validated, regularly inspected and preventively maintained in accordance with the manufacturers’
instructions. Where equipment or materials affect critical processing or storage parameters (e.g., temperature, pressure, particle counts, microbial
contamination levels), they must be identified and must be the subject of appropriate monitoring, alerts, alarms and corrective action, as required, to detect
malfunctions and defects and to ensure that the critical parameters are maintained within acceptable limits at all times. All equipment with a critical measuring
function must be calibrated against a traceable standard if available. Maintenance, servicing, cleaning, disinfection and sanitation of all critical equipment must be
performed regularly and recorded accordingly.
Production processes must be described in detail (equipment, materials, culture media, additives, culture conditions, purification steps,..) in standard operating
procedures (SOPs) and must be validated (procedures published in relevant peer-reviewed journals could be considered ‘validated’).
SOPs must detail the specifications for all critical materials and reagents. In particular, specifications for culture media, additives (e.g., solutions) and packaging
materials must be defined. Critical reagents and materials must meet documented requirements and specifications and when applicable the requirements of
Council Directive 93/42/EEC of 14 June 1993 concerning medical devices and Directive 98/79/EC of the European Parliament and of the Council of 27
October 1998 on in vitro diagnostic medical devices. If possible, animal component free culture media and additives should be used (the Note for Guidance on
Minimizing the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products (EMEA/410/01) in its current
version is to be applied). If animal–product free media are not used, Transmitting Animal Spongiform Encephalopathy (TSE)-free certification should be obtained
for all components containing products of animal origin.
Analytical methods can be validated according to: a) EMEA/CHMP/EWP/192217/2009 “Guideline on bioanalytical method validation” or b) CPMP/ICH /381/95
“ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology”.
Bacteria and phage bank systems need to be set up. These bank systems typically consist of Master seed lots and Working seed lots. The generation and
characterization of the banks should be performed in accordance with principles of CPMP/ICH guideline Q5D. The banked phages and bacteria should be
characterized for relevant phenotypic and genotypic markers so that the identity, viability (activity for phages), and purity of organisms used for the production
are ensured. Biological Resource Centers [10] could function as repositories for bacteriophage Master Seeds and host bacteria.
C. Quality Assurance and Quality Control (QA/QC) specifications
Products/characteristics Control test Limits of acceptance Recommended test procedures
C.1. Host bacteria used in production (stock suspensions)
The bacterial hosts used in the production process – with the exception of selection, adaptation and efficiency of plating (EOP) and host range determination –
should be as safe (or least pathogenic) as feasible.
Origin Document pedigree/
history/pathogenicity
level
Known origin Screening of scientific literature, lab
books, consignment letters,..
Identification Identification at the species
and strain levels
Matching species and strain identification • State of the art clinical microbiology
techniques
• Highly discriminating (molecular/
genomic) typing techniques (e.g.,
MLST, AFLP, PFGE, Rep-PCR,..)
Most often it will not be possible to find or
quickly generate a suitable host
bacterium that is free of prophages or
phage-like elements, but one should
nevertheless strive to use non-lysogenic
strains, containing as few phages or other
phage-like elements of genetic exchange
[11, 12] as possible
• Induction of phages As few spontaneously produced (or by
induction) temperate phages, complete
prophage sequences or phage-like ele-
ments as possiblea
• In vitro induction methods
(Mitomycine C [13] or UV
induction)
• Host genome screening
for phage or phage-like
elements
• State of the art DNA sequencing and
analysis (bioinformatics) procedures
Avoid mutator strains as host bacteria Screen for mutator strains in
case of doubt
No mutator strain State of the art tests (e.g., fosfomycin
and rifampicin Disk Diffusion Tests)
[14]
Validated preservation/storage (cryopreser-
vation, freeze-drying,..)
Monitor storage conditions
(e.g., temperature)
Variable, depending on the preservation
method
Variable (e.g., temperature probes,
temperature indicator labels,..)
C.2. Bacteriophages (Master Seed lots)
Origin • Known origin
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Document bacteriophage
pedigree/history (e.g.,
isolation source)
Screening of scientific literature, lab
books, consignment letters,…
• Natural or naturally evolved
bacteriophages
Identification • Identification at the family
(subfamily), genus and
species and strain level
Matching identification, morphology and
biology
• State of the art DNA or RNA
sequencing and analysis procedures
• Morphology and biology • Highly discriminating genotyping
techniques (e.g., AFLP, fRFLP [15])b
• State of the art classification according
to the International Committee on
Taxonomy of Viruses (ICTV)
• State of the art electron microscopy
(optional)c
• One step growth curve [16]
Not containing potentially damaging genetic
determinants (e.g., conferring toxicity,
virulence, lysogeny or antibiotic
resistance)
Genome analysis for known
potentially damaging
genetic determinants
Absence of potentially damaging genetic
determinantsd
• State of the art DNA or RNA
sequencing and genome analysis
(bioinformatics) procedures
Non-transducing (optional) [17] Screen for ‘general
transduction’
Does not pack random host DNA in a
portion of progeny phage particlese
Transduction assay [18]
In vitro efficacy Determination of host range
on a panel of target
species (reference) strains
Broad host range (if possible) • Titration of bacteriophages against
target bacteria according to the soft-
agar overlay method [19]
Variable threshold according to species (e.g.,
>75% for Staphylococcus aureus) • Spot test [16]
Stability of lysis (optional)f Stable lysis in broth culture for 24–48 h Appelmans method [20]
Efficiency of plating (EOP)
under conditions similar
to eventual clinical appli-
cation (optional)
Threshold EOP value EOP determination [19]
Determination of frequency
of emergence of phage-
resistant bacteria
Low frequency of emergence of resistance Method described by Adams [19]
Improvement / adaptation / ‘training’ (if
warranted)
Optimization of host range Broadened and stable host range • Titration of bacteriophages against
target bacteria according to the soft-
agar overlay method [16]
• Spot test [16]
Validated preservation/storage (cryopreser-
vation, freeze-drying,..)
Monitor storage conditions
(e.g., temperature)
Variable, depending on the preservation
method
Variable (e.g., temperature probes,
temperature indicator labels,..)
C.3. Bacteriophages (Working Seed lots/Active Substances)
Quantitative determination of active
substance (bacteriophages)
Bacteriophage titration Variable. Typically log(8) – log(10) plaque
forming units (pfu)/ml
Soft-agar overlay method [19]
Identification of active substance Genomic fingerprinting Matching genomic fingerprint (max.
deviation depends on method)
State of the art genotyping techniques
(e.g., AFLP, fRFLP [15])
Microbial contamination Sterility (when there is no
sense of urgency)g
Sterile (absence of micro-organisms) Membrane filtration method based on
the European Pharmacopoeia (EP)
Absence of pathogens
(when there is a sense of
urgency)
Aseptic (absence of pathogens) State of the art clinical microbiology
methods
Toxicity Bacterial endotoxin or
lipopolysaccharides (LPS)
quantification [21]
Depends on posology and method and
route of administration. The maximum
level for intravenous applications for
pharmaceutical and biological products is
set to 5 endotoxin units per kg of body
weight per hour (EP).
Limulus Amebocyte Lysate (LAL) assay
according to the EP (e.g., kinetic-
QCL method)
Bacterial DNA contaminationh Screen for (potentially
damaging) host bacterial
DNA
Absence of potentially damaging genetic
determinants that are known to be
present in the host bacterium
Methods for the quantification of
bacterial DNA in general (e.g.,
PicoGreen) or for the quantification
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of known DNA sequences (e.g.,
qPCR)i
Acidity or basicity of aqueous solution pH measurement Variable (typically 6,5–7,5) pH test (EP method)
Purity Clarity of phage solution Absence of visible particles EP method, CPMP-ICH guideline
Validated preservation/storage (cooling,
cryopreservation, freeze-drying,..)
Monitor/record/
demonstrate storage
conditions
(temperature,..)
Variable (e.g., 2–8°C) Variable (e.g., temperature probes,
temperature indicator labels,..)
C.4. Finished products
Bulk products may be diluted (typically to log(5)–log(7) pfu/ml), combined or added to a carrier (hydrogel, ointment, cream, bandage,..) prior to clinical use.
Dilution solutions, carriers and packaging materials must meet documented requirements and specifications and when applicable the requirements of Council
Directive 93/42/EEC of 14 June 1993 concerning medical devices. Carriers must be chosen that allow the required phage activity during the intended
application period (stability).
The following information must be provided either on the label or in accompanying documentation: (a) description (definition) and, if relevant, dimensions of the
bacteriophage product; (b) date of production of the bacteriophage product (c) storage recommendations; (d) instructions for opening the container, package,
and any required manipulation/reconstitution; (e) expiration dates (incl. after opening/manipulation); (f) instructions for reporting serious adverse reactions and/
or events; (g) presence of potentially harmful residues (e.g., antibiotics, ethylene oxide); (h) contraindications; (e) how to dispose of unused (expired)
bacteriophage products.
Validated storage (cold storage,..) Monitor/record/
demonstrate storage
conditions
(temperature,..)
Variable (e.g., 2–8°C) Variable (e.g., temperature probes,
temperature indicator labels,..)
D. Shelf life of phage stock suspensions, working solutions and finished products (at recommended storage conditions)
Stability • Periodic quantitative
determination of the
active substances
(bacteriophages) or
breakdown products
The shelf life is the time period during which
the product remains sterile and the
activity and pH remain within specified
limit thresholds
• Soft-agar overlay method [15]
• Periodic determination of
sterility
• CPMP-ICH guideline, Q5C, Q1A
• Periodic pH
measurements
• Membrane filtration method (EP
method)
• pH test (EP method)
E. Surveillance
The clinical use of phage therapy products must be surveyed and reported, including possible adverse events and reactions associated with the use of phage
therapy products. A centralized (publicly available) reporting system is warranted.
a Today it may be impossible to successfully cure some host strains that are indispensable for the production of some therapeutically interesting phages. In addition,
in some cases it might be necessary to use phages that were isolated from the patient’s bacteria and that are not able to replicate in known host strains devoid of
prophages. However, since that sort of phage preparations are only designed to be used in that given patient, any remaining traces of DNA from that host
bacterium would be orders of magnitude less than the amount already present in the patient from whom that bacterium was isolated for this purpose
b This genetic fingerprint can be used to timely identify bacteriophages and confirm their presence inWorking Seed lots and in finished products, without having to
re-perform full genome sequencing. It is however expected that fast, low-cost and accurate full genome sequencing and analysis (of bacteriophages) will replace
routine microbial genotyping techniques in the near future
c In some cases (e.g., novel bacteriophages with no homology in databases), electron microscopy could provide important information and could thus be
warranted
d In general, it is recommended to only use lytic phages (and no temperate phages) in phage therapy. Lytic phages are more potent killers of host bacteria, making
them more effective in therapy than temperate phages. Following lysogenic induction, temperate phages may transfer fragments of host bacterial DNA into non-
targeted bacteria (possibly belonging to other species). This phenomenon is called transduction or phage-mediated horizontal gene transfer (HGT). If these DNA
fragments contain toxin-encoding or antibiotic resistance-mediating genes, temperate phages could thus produce new pathogenic strains. However, in the future,
the dogma that the use, in treatment, of temperate phages is impossible or undesirable because of the danger of HGT might be abandoned in certain
circumstances (science- and risk-based decision, taking into consideration the patients’ needs). In certain bacterial species, the number of strictly virulent phages is
small and it might not be possible to isolate adequate new virulent phages in due time. Phage mediated HGT is abundant and virtually ubiquitous in bacterial
populations and the additional and immediate danger to the patient related to the use of temperate phages in the course of phage therapy (days) is bound to be
limited. Moreover, if a temperate phage acts as a lytic phage in relation to a particular pathogen, the probability of HGT might not be higher than for inherent
genetic virulent phages [22]. In the future, temperate phages might specifically be used in therapy, e.g., to introduce, by lysogenization, genes conferring sensitivity
to antimicrobials [23] or to inhibit virulence traits [24]. Finally, antibiotic stress was also shown to induce genetic transformability in human pathogens [25]
e Today, it is not feasible to exclude the possibility of low levels of generalized transduction by therapeutic phages into any of the infecting and commensal bacteria
present in or on the patient. The use in phage therapy of phages that mediate some random general transduction might be considered in certain circumstances
(science- and risk-based decision, taking into consideration the patients’ needs)
Phage Product Quality and Safety Requirements
Notwithstanding the Intellectual Property (IP) and regulatory
hurdles, as well as the empirical evidence suggesting that stable
and widely distributed phage preparations (prêt-à-porter) will need
to be constantly updated, a few companies have picked up the
gauntlet and are slowly moving along the elaborate and expen-
sive conventional medicinal product licensing pathway. The
development and marketing of phage medicinal products in
the EU – including Good Manufacturing Practice (GMP) pro-
duction, preclinical and Phase I, II and III clinical trials and
centralized marketing authorization – is in fact technically possi-
ble (and indeed advisable for some products), providing some
minor modifications and logical exemptions are made.
However, multiple discussions between experts, com-
petent authorities and policymakers have led to an
increasing awareness that sustainable (sur-mesure) phage
therapy is not compatible with the conventional ap-
proaches to the development and application of medic-
inal products [4]. Next to the classical medicinal prod-
uct pathway, which should be adjusted to support the
industrial production of (first line) broad-spectrum phage
cocktails or phage-derived products (e.g., phage
endolysins), there is a need for a specific framework
(including realistic production and quality and safety
requirements) that allows a timely (rapid) supplying of
adapted productions of natural bacteriophages for ‘per-
sonalized therapy’. This regulatory framework could be
based on the Quality by Design (QbD) concept, which
is increasingly applied to the development and produc-
tion of biopharmaceutical molecules [7]. The QbD ap-
proach entails designing quality into the process and the
product, and this in a science- and risk-based manner.
Understanding patients’ needs and determining the spe-
cific science and quality characteristics of the product
that are linked to safety and efficacy are crucial com-
ponents of QbD. More research is urgently needed to
gather the required data with regard to the efficacy of
phage therapy and to broaden our understanding of
bacteria-phage coevolution in nature and in the context
of human disease [8, 9]. To avoid the mistakes of the
past (which lead to the current antibiotic resistance
crisis), phage therapy products should not exclusively
be developed and marketed as antibiotics, i.e., applying
current pharmacoeconomic principles. Ideally, phage
therapy should be coordinated and standardized (in a
first instance) by national phage therapy centers, which
operate under the supervision of relevant public health
authorities and in interaction with private stakeholders.
There are precedents for such a dedicated ‘non-me-
dicinal product’ approach. In the European Union
(EU), human tissues and cells that are not considered
as ‘Advanced Therapy Medicinal Products (ATMPs)’ are
procured, processed, tested and allocated by (or under
the responsibility of) dedicated tissue establishments and
are exclusively regulated by the EU Tissue and Cell
Directives (EUTCDs). The EUTCDs consist of three
Directives, the parent Directive (2004/23/EC), which
provides the framework legislation, and two technical
Directives (2006/17/EC and 2006/86/EC), which pro-
vide the detailed requirements of the EUTCD. The
purpose of these Directives was to facilitate a safer
and easier exchange of human tissues and cells between
member states and to improve safety standards for Eu-
ropean citizens. They set a benchmark for the standards
that must be met when carrying out any activity involv-
ing tissues and cells for human application.
In view of further meetings with phage experts and
representatives of the competent authorities and
policymakers – coordinated by the European Commis-
sion Joint Research Centre, which acts in an advisory
capacity to the Commission and its policy making di-
rectorates general –, a group of ‘phage experts’ (the
authors of this paper) were asked through the interme-
diary of a not-for-profit organization (www.p-h-a-g-e.
org) to set realistic quality and safety requirements for
sustainable phage therapy products (Table I). These
requirements are intended to apply to the production
of phage therapy products (finished products), starting
from banked characterized natural therapeutic bacterio-
phages (Master Seed lots), and possibly using intermedi-
ate bacteriophage products (Working Seed lots or Active
Substances). They were roughly based on the EUTCD
quality and safety standards for human cells and were
f In some cases, phages that produce stable lysis will not be found in a timely fashion. Phages that induce relatively fast in vitro bacterial resistance might then be
considered
g In some cases, sterility may not be required (e.g., ‘non-sterile for topical application’)
hWorking Seed lots can be contaminated with low levels of DNA derived from the host bacteria used in production. Potentially damaging genetic determinants
(e.g., conferring toxicity, virulence or antibiotic resistance) might then be transferred (through transformation) to bacteria present in or on the patient, which could
potentially make them (more) pathogenic. While this would be expected to occur at a level well below exchanges already going on within the patient’s body
involving their own pathogenic bacteria and phages already resident it makes sense to select hosts that are as devoid of pathogenicity factors as reasonably possible
for growing therapeutic phage and treating the phage with DNase in the course of their purification to destroy such contaminants. If no non-pathogenic bacterial
strain is available for growing the phage, constructing a ‘defanged’ host strain, with all pathogenicity determinants deleted, could be envisaged as the best main step
in avoiding this issue. Note that the use of non-pathogenic host bacterial strains also reduces the potential hazard to the personnel involved in the production of
therapeutic phages
i A threshold level should be determined. Note that some DNA quantification methods might also pick up phage DNA
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defined by consensus among 32 phage experts (biolo-
gists, geneticists, bioengineers, quality managers, phar-
macists and MDs) from 12 countries. This document
enumerates all possible phage product related quality
and safety risks known to the experts, as well as the
tests that can be performed to minimize these risks, only
to the extent needed to protect the patients and to
allow and advance responsible phage therapy and re-
search. The exact tests used and limits applied will
depend on the route of administration (e.g., topical or
systemic) and the regulatory path the product is being
used under. These requirements do not address efficacy
aspects of phage therapy products.
Should bacteriophages be used for a public health or
medical emergency and no adequate finished products,
Master Seed lots or Working Seed lots are available,
then less stringent requirements could be considered,
pending compliance (as quick as possible) to the quality
and safety requirements.
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